---
title: "FDA approves Elevar Therapeutics' Rivoceranib + camrelizumab?"
canonical_url: https://betcrypto.now/events/fda-approves-elevar-therapeutics-rivoceranib-camrelizumab
status: settled
trading_closes_at: 2026-07-23T00:00:00+00:00
settled_at: 2026-07-11T11:54:41+00:00
total_volume_usd: 1782.79
venues: ["Polymarket"]
categories: ["Tech & Science"]
prices_as_of: 2026-10-09T19:54:25+00:00
publisher: BetCrypto
data_api: https://betcrypto.now/api/v1/events/fda-approves-elevar-therapeutics-rivoceranib-camrelizumab
---

# FDA approves Elevar Therapeutics' Rivoceranib + camrelizumab?

Settled · $1,783 traded · listed on Polymarket

## Result

**No** won. Settled 2026-07-11.

## About

As of market creation, the FDA's expected decision date for the specified application is July 23, 2026.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Elevar Therapeutics's Rivoceranib in combination with camrelizumab as a treatment for first-line unresectable or metastatic hepatocellular carcinoma by August 6, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately.

If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

_From Polymarket's listing._

## Open on a venue

- [Polymarket](https://betcrypto.now/go/e/20611?via=md)

---

Probability is the cross-venue consensus (book midpoints, 0–100%). Venue columns are what buying costs there (the ask). Prices move constantly; re-check at the canonical URL or https://betcrypto.now/api/v1/events/fda-approves-elevar-therapeutics-rivoceranib-camrelizumab.

BetCrypto is an odds-comparison and information service. It accepts no wagers and gives no betting or financial advice; prediction-market availability depends on where you live.